Dr Siefker-Radtke shares takeaways from the SOGUG-AUREA study and its influence on treatment for patients with urothelial cancer.
Arlene Siefker-Radtke, MD: We often look at discontinuation rates when we consider the toxicity of these [treatment] strategies. What we’re seeing from atezolizumab [Tecentriq] and split-dose cisplatin in this trial is that the majority of patients come off treatment due to progressive disease or lack of clinical activity, which is very common with systemic chemotherapy agents. It also doesn’t appear that this combination is contributing to additional toxicity. At the moment, the split-dose cisplatin trial tells us that we can use split-dose cisplatin safely. We see clinical activity with good objective response rates. It’s still too early to tell if the survival is going to be similar to cisplatin-based regimens or more closely relevant to carboplatin-based regimens. I look forward to seeing further follow-up from this trial to give us a more definitive end point on what the survival is in this patient cohort.
I’m also asked, “Where should we go next with this SOGUG-AUREA trial with gemcitabine-cisplatin with or without atezolizumab?” The split dose is a very attractive option for patients with borderline kidney function, and one that I’ll continue to utilize in my patients with bladder cancer. But whether to incorporate atezolizumab remains an unanswered question. To do this with the current trial would take a larger randomized phase 3 clinical trial. Personally, I’d wait to see if we have further follow-up from the atezolizumab frontline trial suggesting whether it meets an overall survival end point as the imprimatur of whether we should give atezolizumab with systemic chemotherapy. With the available trials, we’ll have enough data to tell us whether we should ever consider giving split-dose cisplatin with an immune checkpoint inhibitor.
Transcript edited for clarity.
Patients With HFrEF, HFpEF See Different Functional Capacity Benefits With Dapagliflozin
December 7th 2023The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.
Read More
Black Patients With Ulcerative Colitis Less Likely to Undergo IPAA Than White Patients
December 7th 2023Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA) decreased.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More
New Investigation Analyzes Magnetic Resonance Measures of DMD for Disease Progression
December 7th 2023Investigators evaluated longitudinal MRI and spectroscopy outcomes and ambulatory function among 180 patients with Duchenne muscular dystrophy (DMD) to establish the utility and reproducibility of magnetic resonance measures of muscle quality at different disease stages.
Read More